Multidrug resistance-1 (MDR-1) in autoimmune disorders IV. P-glycoprotein overfunction in lymphocytes from myasthenia gravis patients

Biomedicine and Pharmacotherapy

Volumn 58, Issue 5, 2004, Pages 320-324

  Richaud Patin, Yvonne ^a   Vega Boada, Felipe ^a   Vidaller, Antonio ^b   Llorente, Luis ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Multidrug resistance 1; Myasthenia gravis; P glycoprotein

Indexed keywords

CORTICOSTEROID; DAUNORUBICIN; GLYCOPROTEIN P; PREDNISONE;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOCYTE; MALE; MONONUCLEAR CELL; MULTIDRUG RESISTANCE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADOLESCENT; ADULT; AZATHIOPRINE; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; P-GLYCOPROTEIN; PREDNISOLONE;

EID: 2942542936     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2004.04.008     Document Type: Article

References (22)

1. Vincent A., Palace J., Hilton-Jones D. Myasthenia gravis. Lancet. 357:2001;2122-2128
2. Newsom-Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol. 23:2003;191-198
3. Ling V. Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 40:(Suppl 1):1997;53-58
4. Deeley R.G., Cole S.P.C. Function, evolution and structure of multidrug resistance protein. Semin Cancer Biol. 8:1997;193-204
5. Ford J.M. Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am. 9:1995;337-361
6. Chan H.S.L., De Boer G., Thurner P.S., Haddad G., Gallie B.L., Ling V. Multidrug resistance. Clinical opportunities in diagnosis and circumvention. Hematol Oncol Clin North Am. 8:1994;383-410
7. Tellez-Zenteno J.F., García-Ramos G., Garduño-Espinoza J., et al. Diagnostic test in myasthenia gravis. Gold standard conformation by a consensus. Rev Neurol. 33:2001;825-832
8. Lee C.G., Gottesman M.M. HIV protease inhibitors and the MDR-1 multidrug transporter. J Clin Invest. 101:1998;287-288
9. Siddiqui A., Kerb R., Weale M.E., et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New Engl J Med. 348:2003;1442-1448
10. Farrell R.J., Murphy A., Long A., et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 118:2000;279-288
11. Llorente L., Richaud-Patin Y., Díaz-Borjón A., et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I. Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine. 67:2000;30-39
12. Jorgensen C., Maillefert J.F. Multidrug resistance genes in rheumatology: is their role immunological or pharmacological? Joint Bone Spine. 67:2000;8-10
13. Díaz-Borjón A., Richaud-Patin Y., Alvarado de la Barrera C., Jakez-Ocampo J., Ruiz-Argüelles A., Llorente L. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part II. Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine. 67:2000;40-48
14. Levy A.S., Cunningham-Rundles S., Mazza B., Simm M., Gorlick R., Bussel J. High P-glycoprotein mediated export observed in patients with a history of idiopathic thrombocytopenic purpura. Br J Haematol. 118:2002;836-838
15. Ruiz-Soto R., Richaud-Patin Y., López-Karpovitch X., Llorente L. Multidrug resistance-1 (MDR-1) in autoimmune disorders. III. Increased P-glycoprotein activity in lymphocytes from immune thrombocytopenic purpura patients. Exp Hematol. 31:2003;483-487
16. Kapplemayer J., Karazi E., Telek B., Jakab K. "Pros and cons" on how to measure multidrug resistance in leukemias. Leuk Lymphoma. 43:2002;711-717
17. McClean S., Hill B.T. Evidence of post-translational regulation of P-glycoprotein associated with the expression of a distinctive multiple drug resistance phenotype in Chinese hamster ovary cells. Eur J Cancer. 29A:1993;2243-2248
18. Richaud-Patin Y., Soto-Vega E., Jakez-Ocampo J., Llorente L. P-glycoprotein in autoimmune diseases. Autoimmunity Rev. 3:2004;188-192
19. Distelhorst C.W., Dubyak G. Role of calcium in glucocorticosteroid- induced apoptosis of thymocytes and lymphoma cells: resurrection of old theories by new findings. Blood. 91:1998;731-734
20. Vilpo J., Koski T., Vilpo L. Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro. Haematologica. 85:2000;806-813
21. Cornwell M.M., Pastan I., Gottesman M.M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem. 262:1987;2166-2170
22. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP transporters. Nat Rev Cancer. 2:2002;48-58